Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 5

Results For "Myeloma"

53 News Found

Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer
People | February 23, 2022

Sumitomo Dainippon Pharma Oncology appoints Jatin J. Shah as Chief Medical Officer

Dr. Shah will lead strategic and operational clinical development of the company's diverse pipeline


Sandoz launches generic lenalidomide in 19 countries across Europe
Biotech | February 18, 2022

Sandoz launches generic lenalidomide in 19 countries across Europe

Lenalidomide Sandoz is indicated for use in several critical haematology-oncology conditions, per latest ESMO guidelines


Bristol Myers Squibb receives approval for Abecma in Japan
Drug Approval | January 21, 2022

Bristol Myers Squibb receives approval for Abecma in Japan

It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan


Novartis announces next-generation CAR-T platform, T Charge
Biotech | December 14, 2021

Novartis announces next-generation CAR-T platform, T Charge

T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies


Novartis showcases its attractive growth pipeline
News | December 03, 2021

Novartis showcases its attractive growth pipeline

Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint


Sanofi invests US $ 180 mn in Owkin’s AI for oncology pipeline
Biotech | November 26, 2021

Sanofi invests US $ 180 mn in Owkin’s AI for oncology pipeline

Owkin builds best-in-class predictive biomedical AI models and robust data sets


WHO new Essential Medicines Lists focus on diabetes and cancer
Public Health | September 30, 2021

WHO new Essential Medicines Lists focus on diabetes and cancer

The listings aim to address global health priorities, identifying the medicines that provide the greatest benefits, and which should be available and affordable for all


Biocon settles suit with Celgene for generic Revlimid
Biotech | September 08, 2021

Biocon settles suit with Celgene for generic Revlimid

Revlimid is a blood cancer drug with sales of US $ 12.1 billion in 2020


Natco Pharma launch Nat-Lenalidomide in Canada
Drug Approval | September 02, 2021

Natco Pharma launch Nat-Lenalidomide in Canada

Nat-Lenalidomide, a generic alternative to Revlimid, expands affordable treatment options for patients with multiple myeloma and patients with transfusion-dependent anaemia due to myelodysplastic syndromes (MDS)


Reddy-Lenalidomide launched in Canada
Drug Approval | September 02, 2021

Reddy-Lenalidomide launched in Canada

Dr. Reddy's Laboratories Canada announces the launch of Reddy-Lenalidomide, one of the first generic medications of its kind for the Canadian market